SG11201811595SA - Liponucleotide-based therapy for ards - Google Patents
Liponucleotide-based therapy for ardsInfo
- Publication number
- SG11201811595SA SG11201811595SA SG11201811595SA SG11201811595SA SG11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cdp
- rule
- ards
- pct
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract 2
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355096P | 2016-06-27 | 2016-06-27 | |
| PCT/US2017/039545 WO2018005527A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811595SA true SG11201811595SA (en) | 2019-01-30 |
Family
ID=60786443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811595SA SG11201811595SA (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10874684B2 (enExample) |
| EP (2) | EP4292651A3 (enExample) |
| JP (1) | JP2019518798A (enExample) |
| KR (1) | KR20190022682A (enExample) |
| CN (1) | CN109475554A (enExample) |
| AU (1) | AU2017289278A1 (enExample) |
| CA (1) | CA3029005A1 (enExample) |
| SG (1) | SG11201811595SA (enExample) |
| WO (1) | WO2018005527A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475554A (zh) * | 2016-06-27 | 2019-03-15 | 俄亥俄州国家创新基金会 | 基于脂核苷酸的ards治疗 |
| WO2019005898A1 (en) | 2017-06-27 | 2019-01-03 | Ohio State Innovation Foundation | LIPONUCLEOTID THERAPY FOR COPD |
| EP4125857A4 (en) * | 2020-03-31 | 2024-04-17 | Diffusion Pharmaceuticals LLC | USE OF DIFFUSION ENHANCEMENT COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE INDUCED BY VIRUSES AND BACTERIA |
| US12440464B2 (en) | 2020-05-01 | 2025-10-14 | Irazu Bio | Method for treating respiratory viral infections comprising administration of fatty acid compositions |
| WO2023173043A1 (en) * | 2022-03-11 | 2023-09-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection |
| WO2023177995A2 (en) * | 2022-03-18 | 2023-09-21 | Ohio State Innovation Foundation | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| DE3883374T2 (de) * | 1987-10-28 | 1993-12-09 | Pro Neuron Inc | Acylatiertes uridin und cytidin und deren verwendungen. |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| WO1996001115A1 (en) * | 1994-07-01 | 1996-01-18 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| US20040049022A1 (en) * | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| EP2329828A1 (en) * | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of ischaemia |
| EP1453844B1 (en) * | 2001-11-21 | 2013-11-20 | University of Aarhus | Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| MX2007005975A (es) * | 2004-11-17 | 2007-10-08 | Yissum Res Dev Co | Uso de conjugados de lipido en el tratamiento de enfermedades. |
| CA2645647C (en) * | 2005-05-23 | 2016-07-12 | Massachusetts Institute Of Technology | Compositions containing pufa and/or uridine and methods of use thereof |
| CN101495490B (zh) * | 2005-05-23 | 2018-05-08 | 麻省理工学院 | 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法 |
| CN109475554A (zh) * | 2016-06-27 | 2019-03-15 | 俄亥俄州国家创新基金会 | 基于脂核苷酸的ards治疗 |
| EP3645010A4 (en) * | 2017-06-27 | 2021-03-24 | Ohio State Innovation Foundation | NUCLEOTIDE-BASED THERAPY FOR ASTHMA |
| WO2019005898A1 (en) * | 2017-06-27 | 2019-01-03 | Ohio State Innovation Foundation | LIPONUCLEOTID THERAPY FOR COPD |
-
2017
- 2017-06-27 CN CN201780039385.4A patent/CN109475554A/zh active Pending
- 2017-06-27 EP EP23207788.3A patent/EP4292651A3/en active Pending
- 2017-06-27 WO PCT/US2017/039545 patent/WO2018005527A1/en not_active Ceased
- 2017-06-27 EP EP17821089.4A patent/EP3474853A4/en not_active Withdrawn
- 2017-06-27 SG SG11201811595SA patent/SG11201811595SA/en unknown
- 2017-06-27 KR KR1020197002042A patent/KR20190022682A/ko not_active Ceased
- 2017-06-27 AU AU2017289278A patent/AU2017289278A1/en not_active Abandoned
- 2017-06-27 JP JP2019519626A patent/JP2019518798A/ja active Pending
- 2017-06-27 CA CA3029005A patent/CA3029005A1/en active Pending
-
2018
- 2018-12-21 US US16/230,225 patent/US10874684B2/en active Active
-
2020
- 2020-11-19 US US16/952,557 patent/US20210069225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10874684B2 (en) | 2020-12-29 |
| CN109475554A (zh) | 2019-03-15 |
| EP4292651A2 (en) | 2023-12-20 |
| AU2017289278A1 (en) | 2019-01-17 |
| WO2018005527A1 (en) | 2018-01-04 |
| EP3474853A4 (en) | 2020-02-19 |
| EP4292651A3 (en) | 2024-03-13 |
| EP3474853A1 (en) | 2019-05-01 |
| KR20190022682A (ko) | 2019-03-06 |
| US20190134074A1 (en) | 2019-05-09 |
| CA3029005A1 (en) | 2018-01-04 |
| US20210069225A1 (en) | 2021-03-11 |
| JP2019518798A (ja) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811595SA (en) | Liponucleotide-based therapy for ards | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201408810TA (en) | Methods of treating arthritis | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201909419XA (en) | Hydrogel for cell culture and biomedical applications | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201805001UA (en) | Method of treating influenza a |